Form 4: Sarepta CFO Ryan Wong Granted 118,875 RSUs

Sarepta Therapeutics' Chief Financial Officer, Ryan Ho-Yan Wong, received a grant of 118,875 restricted stock units, vesting over several years and tied to continued service and performance.

Summary

• Ryan Ho-Yan Wong, Chief Financial Officer of Sarepta Therapeutics, Inc. (SRPT), was granted a total of 118,875 restricted stock units (RSUs) on September 3, 2025.
• The grant comprises two tranches: 93,875 RSUs and 25,000 RSUs.
• The 93,875 RSUs will vest in two equal installments: 50% on September 3, 2026, and the remaining 50% on September 3, 2027, contingent upon Mr. Wong's continued service to the company.
• The 25,000 RSUs are performance-based and will vest 100% on September 3, 2028, subject to Mr. Wong's continued service and the achievement of specific performance criteria as determined by the Compensation Committee of the Board.
• Following these transactions, Mr. Wong's direct beneficial ownership of Sarepta Therapeutics common stock increased to 136,203 shares.

Sentiment

Score: 7

Explanation: The grant of performance-based and time-based restricted stock units to a key executive like the CFO is a positive signal for executive retention and aligns management's long-term interests with shareholder value creation, which is generally viewed favorably.

Positives

• The equity grant aligns the Chief Financial Officer's long-term interests with those of shareholders, incentivizing value creation.
• The inclusion of performance-based vesting for a portion of the RSUs ties executive compensation directly to the achievement of strategic company goals.
• The grant serves as a retention mechanism for a key executive, ensuring continuity in leadership.

Negatives

• The issuance of new restricted stock units, upon vesting, will result in a minor dilutive effect on existing shareholders.

Risks

• The vesting of the restricted stock units is contingent on the Reporting Person's continued service to the Company, meaning forfeiture if employment ceases.
• The vesting of 25,000 RSUs is also subject to the achievement of certain performance criteria, which may or may not be met.

Future Outlook

The future outlook primarily involves the vesting of the granted restricted stock units, with 50% of the 93,875 RSUs vesting on September 3, 2026, and the remaining 50% on September 3, 2027. The 25,000 performance-based RSUs are set to vest on September 3, 2028, contingent on specific performance criteria being met.

Industry Context

This Form 4 filing is specific to an individual executive's compensation and does not provide broader industry trends or competitive analysis.

Related Party Transactions

• Grant of restricted stock units to Chief Financial Officer Ryan Ho-Yan Wong as part of his compensation package.

Stakeholder Impact

• Shareholders: Potential minor dilution upon vesting, but increased alignment of executive incentives with long-term company performance.
• Employees: No direct impact on general employees; this is specific to executive compensation.

Next Steps

• Continued service of the Chief Financial Officer to the company.
• Vesting of 50% of 93,875 RSUs on September 3, 2026.
• Vesting of the remaining 50% of 93,875 RSUs on September 3, 2027.
• Assessment of performance criteria by the Compensation Committee for the 25,000 RSUs.
• Vesting of 25,000 performance-based RSUs on September 3, 2028, if criteria are met.

Key Dates

Recommendation

This Form 4 filing details a routine equity compensation grant to a key executive, which is a standard practice for executive retention and incentive alignment. It does not provide new information that would fundamentally alter the investment thesis for Sarepta Therapeutics, hence a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Sarepta Therapeutics, SRPT, Ryan Ho-Yan Wong, CFO, Restricted Stock Units, RSU, Equity Grant, Executive Compensation, Insider Ownership, Form 4